A recent study has raised significant concerns regarding the use of widely consumed NAD+ supplements in the United States, suggesting that these compounds, often taken to enhance energy levels and promote healthy aging, may adversely affect cancer treatment outcomes. Millions of Americans routinely use supplements such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) in the hope of increasing NAD+ levels, a molecule vital for metabolism and cellular repair.
Interestingly, some cancer patients have started using these supplements to mitigate the harsh effects of chemotherapy. However, emerging evidence indicates this approach might prove counterproductive. Research from Case Western Reserve University’s School of Medicine, published in Cancer Letters, found that vitamin B3 derivatives could actually aid pancreatic cancer cells in surviving treatment. This is alarming, as pancreatic cancer has a five-year survival rate of just 13%, making any factor influencing treatment crucial.
NAD+ is essential for the function of both healthy and cancerous cells. While boosting NAD+ levels may benefit healthy individuals, the study demonstrates that cancer cells could exploit this increased supply to enhance their own energy production and resist treatment-induced cell death. In laboratory and mouse studies, particularly NMN demonstrated the capacity to protect pancreatic cancer cells against three common chemotherapy drugs.
The researchers outlined three primary mechanisms by which these supplements could impede treatment: they enhance cancer cell energy, reduce oxidative stress, and limit both DNA damage and cell death, all of which are vital for chemotherapy efficacy.
Jordan Winter, the study’s lead researcher, highlighted the need for caution regarding NAD+-boosting supplements in cancer patients undergoing chemotherapy. While the study does not suggest these supplements are harmful to healthy individuals, their potential dangers for active cancer patients may be considerable. Consequently, the team advocates for routine assessments of supplement usage in this demographic and recommends further clinical studies to investigate the interactions between NAD+ supplements and cancer therapies. In the meantime, Winter advises patients to consult their oncologists about any supplements they are consuming.
Test Your Understanding
How much do you know?
